Chronoscale Holdings Corp quarterly report, Q2 FY2019

Business context and reporting period

The filing is Ekso Bionics Holdings, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2019; the request metadata names Chronoscale Holdings Corp., which does not match the registrant shown in the filing. Ekso designs and sells medical and industrial exoskeletons. Unless stated otherwise, financial amounts below are in millions of dollars.

Financial results and liquidity

MetricQ2 2019Q2 2018Six months 2019Six months 2018
Revenue$3.262$2.967$6.878$5.486
Gross profit / margin$1.560 / 47.8%$0.967 / 32.6%$3.159 / 45.9%$1.736 / 31.6%
Operating loss$(5.098)$(7.185)$(10.010)$(15.796)
Net loss$(3.066)$(7.978)$(9.617)$(15.877)
Basic and diluted loss per share$(0.04)$(0.13)$(0.14)$(0.26)

Q2 revenue rose 10%; first-half revenue rose 25%. First-half operating cash use was $9.708, versus $12.804 a year earlier. Cash increased to $13.262 from $7.655 at year-end, supported by $15.368 of net financing cash flow; investing cash use was $0.060. At June 30, current assets were $22.133 and current liabilities $9.343. Debt carrying value was $3.868, including $2.333 current and $1.535 long-term; the contractual-obligations table reports $4.181 for term-loan payments. The debt agreement required $4.546 of cash to be maintained under its liquidity covenant; management estimated unrestricted cash at $8.716 and reported covenant compliance.

Material changes and unusual items

  • Q2 gross profit improved chiefly from higher EksoHealth device volume and average selling prices. EksoHealth revenue was $2.840 million in Q2; EksoWorks revenue was $0.414 million. First-half revenue increased in both segments, with the larger increase in EksoHealth.
  • Operating expenses fell 18% in Q2 and 25% in the first half year over year. Management cited reduced sales and marketing activity, lower consulting and legal costs, lower headcount-related costs, and the absence of certain prior-year charges.
  • Net loss improved more than operating loss partly because of noncash warrant revaluation gains: $2.737 million in Q2 and $1.615 million for the first half. The May financing also generated $0.706 million of warrant issuance expense; a warrant modification caused a further $0.257 million first-half loss. Warrant liabilities rose to $6.561 million from $0.585 million at year-end.
  • May’s common-stock-and-warrant offering generated $9.0 million net proceeds; the company also raised $5.0 million in January from JV-related investors and $2.3 million net through its at-the-market program. Shares outstanding increased to 74.895 million from 62.963 million at December 31, 2018. The May warrants cover up to 6.667 million shares and include anti-dilution and change-of-control provisions.
  • Adoption of lease accounting in 2019 added right-of-use assets and lease liabilities; at June 30 these were $1.277 million and $1.327 million, respectively. Management said the adoption did not materially affect operating results or cash flows.

Outlook, commentary and risks

There is no specific revenue or earnings guidance in the filing. Management stated that available cash, assuming modest revenue increases, was expected to fund obligations only until late in Q4 2019; cash was not forecast to cover the next 12 months, raising substantial doubt about the company’s ability to continue as a going concern. It said significant additional financing would be required and was being pursued through equity, debt or corporate collaborations. If financing is unavailable, substantial cost reductions or curtailed operations may be necessary. Further equity issuance could dilute existing holders.

The company reported booking 22 EksoGT units in Q2, including two rentals, and converting 11 previously rented units to capital purchases. In July 2019, after the quarter, it announced EksoUE, an upper-extremity rehabilitation device. Industrial sales efforts included alternative rental channels and global manufacturer relationships.

Risks include uncertain financing, medical-device regulatory approval and reimbursement, clinical-trial outcomes, adoption and sales-cycle variability, competition, foreign-exchange exposure, and customer concentration: one customer represented 31% of Q2 revenue and 21% of first-half revenue. U.S. agencies had inquired about the China joint venture and related investment. The company said it believed the arrangements complied with applicable rules, but CFIUS or export-control review could delay, restrict, or require unwinding the venture or technology transfer. The filing also describes shareholder derivative litigation; management considers the claims without merit. Management reported disclosure controls effective and no material quarterly change in internal controls.

Important facts for investors to verify

  • Confirm the issuer identity: this filing is for Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), not the company named in the request metadata.
  • Track cash burn, the $4.546 million covenant cash requirement, financing availability, and whether management’s late-Q4 2019 liquidity estimate changes.
  • Assess the quality and sustainability of revenue and gross-margin gains, including reliance on a major customer and device sales volumes.
  • Review potential dilution and warrant terms, including the $6.561 million fair-value liability and the 6.667 million May warrant shares.
  • Monitor U.S. government review of the China JV, completion of the IP transfer and JV registration, and the contingent second $5.0 million JV-partner investment.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.